How Long Can You Live With MS With Treatment Today?

People diagnosed with multiple sclerosis today can reasonably expect to live into their seventies or beyond, with the gap between MS life expectancy and the general population shrinking dramatically over the past few decades. A sixty-year population study from British Columbia found median survival of about 75 years for people with MS compared with roughly 82 for the general population, but the most striking finding was how fast that gap is closing: for people diagnosed after 1997, the excess mortality risk essentially disappeared during the study period.¹ That trend reflects the arrival of effective disease-modifying therapies, better infection prevention, and more aggressive early treatment. The honest answer, though, depends heavily on when you’re diagnosed, what type of MS you have, and how quickly you start the right treatment.

The Life Expectancy Numbers in Context

The British Columbia study, which tracked over 6,000 people with MS across six decades, reported median life expectancy of about 77 years for women with MS and 72 for men. The type of MS mattered: people with relapsing-remitting MS (the most common form) had a median life expectancy around 78 years, while those with primary progressive MS lived a median of about 71 years.¹ These numbers, though, blend together people diagnosed across very different treatment eras. The same study found that the standardized mortality ratio (a measure of how much higher the death rate is compared to the general population) dropped from 3.1 for people diagnosed in the 1950s through 1970s to just 0.7 for those diagnosed from 1997 onward. A ratio below 1.0 means, during that follow-up window, the MS group was not dying at a rate higher than expected. That is a remarkable shift.

A large French study added another useful frame: for the first 20 years after diagnosis, survival in people with MS tracked closely with the general population. The curves only began to separate after that point, eventually opening a gap of around seven years.² This means that for many people, especially those diagnosed in the current treatment era, the first two decades after diagnosis look quite normal from a survival standpoint. The risk accumulates later, as disability progresses and secondary complications become more likely.

Why Early, Aggressive Treatment Changes the Trajectory

The single biggest factor in the improving outlook is disease-modifying therapy, and increasingly, the consensus is that starting potent treatment early makes a measurable difference. An expert review in the Journal of Neurology found growing evidence that early use of high-efficacy therapies delays irreversible nervous system damage and slows disability accumulation compared to the older approach of starting with milder drugs and escalating only when they fail.³

A study from Argentina that compared the two strategies directly, using statistical matching to make the groups comparable, found that early high-efficacy treatment cut the risk of disability progression by about a third and reduced relapses and new brain lesion activity by similar margins.⁴ Nine-year data from the OPERA trials reinforced this: among people with early relapsing MS treated with ocrelizumab from the start, nearly four in five had no confirmed disability progression over the full follow-up period. People who switched to ocrelizumab later, after initially receiving an older injectable therapy, never quite caught up in brain volume preservation.⁵ The implication is that the window right after diagnosis is especially valuable. Brain tissue lost early does not come back, even when inflammation is later controlled.

What Actually Kills People With MS

MS itself is rarely listed as the direct cause on a death certificate. The disease instead creates vulnerability to secondary problems, especially infections. A Finnish study of people diagnosed between 1981 and 2010 found that infections, respiratory or otherwise, were the immediate cause of death in over half the cases.⁶ A population-level U.S. study clarified the mechanism: when MS appeared on a death certificate, the odds of aspiration pneumonia contributing to the death were about seven times higher, and urinary tract infections about ten times higher, than when MS was absent.⁷

This makes sense when you consider how advanced MS affects the body. Swallowing difficulties lead to aspiration; impaired mobility leads to skin breakdown and bedsores; neurogenic bladder problems make urinary infections chronic. A Scandinavian study tracking over 450 MS deaths confirmed the pattern, finding significantly elevated mortality from pneumonia and gastrointestinal causes, with the risk growing the longer a person had lived with the disease.⁸ Cardiovascular disease also contributes, particularly in people over 60, and suicide risk is elevated in younger patients. The practical takeaway is that preventing disability progression is not just about quality of life. Keeping someone mobile, continent, and able to swallow safely has a direct line to how long they live.

The Infection Risk Tied to Disability Level

How disabled a person becomes matters enormously for infection risk, independent of MS type. A Swedish register study found that people with progressive MS faced serious infection rates roughly four times higher than matched individuals without the disease. People with relapsing-remitting MS also had elevated risk, but at a lower level. When the researchers stratified by disability score rather than MS type, the pattern was even starker: those with significant walking impairment had about four times the infection risk of the general population, while people with mild disability had only modestly elevated rates.⁹ This underscores why controlling disability progression is central to longevity: the infections that ultimately shorten life in MS are downstream of the physical impairment itself.

How Age at Diagnosis Shapes the Outlook

Being diagnosed later in life generally means a faster path to disability. A Swedish nationwide study found that people diagnosed after age 50 (late-onset MS) reached disability milestones roughly two to three times faster than those diagnosed in the typical young-adult window, even after adjusting for sex and MS type.¹⁰ A French population study confirmed this, finding that late onset independently predicted a faster time to significant disability regardless of whether the person had relapsing or progressive disease.¹¹ Late-onset MS is also more likely to be the progressive form from the start, and in practice, people with late-onset MS are less likely to receive potent therapies, potentially compounding the problem.¹⁰

At the other end of the age spectrum, pediatric-onset MS presents a different pattern. Children and teenagers with MS take longer to reach disability milestones measured from their diagnosis date, but they reach those milestones at a younger chronological age than adults do. A study of pediatric-onset cases found that the median time to needing a cane was about 40 years after diagnosis, which sounds reassuring until you realize that means reaching that point in your fifties.¹² The encouraging news is that this outcome has improved in more recent diagnosis eras, likely because children are now treated earlier and with more effective drugs.¹² Higher relapse rates in the first five years of pediatric MS predicted worse outcomes, while complete recovery from the first relapse was protective.¹³

Comorbidities and Cardiovascular Risk

MS does not exist in a vacuum, and the other health conditions a person carries affect their prognosis significantly. A Canadian study found that diabetes, heart disease, depression, anxiety, bipolar disorder, and chronic lung disease were each independently linked to a higher risk of death in people with MS.¹⁴ Cardiovascular risk deserves special attention. A large English study found that people with MS had about one and a half times the risk of dying from cardiovascular disease compared to matched controls, on top of a substantially elevated all-cause mortality rate.¹⁵ Another study found elevated odds of both ischemic and hemorrhagic stroke in the MS population.¹⁶

The reasons are partly related to reduced mobility and the metabolic consequences that follow, and partly to chronic inflammation. Either way, managing blood pressure, blood sugar, and cholesterol matters for people with MS just as much as managing their MS medications, and arguably more as they age.

Smoking, Exercise, and Modifiable Factors

Among lifestyle factors, smoking stands out as both a risk factor for developing MS and an accelerator of its progression. A review in the Journal of Inflammation Research found that smoking adversely influences disease progression, though the evidence on specific symptoms was still building at the time of publication.¹⁷ A separate study that followed MS patients over 15 years found that smoking at baseline raised the mortality risk by about 38 percent after adjusting for disability, mental health, and other conditions. On the flip side, physical activity was strongly protective: exercising three or more times per week was associated with roughly half the mortality risk compared to being inactive.¹⁸ These are some of the largest modifiable effects in the MS literature. For someone looking to maximize their time and quality of life, quitting smoking and staying as physically active as possible are probably the highest-return investments outside of medication.

Blood Biomarkers That Predict Long-Term Outcomes

One of the more exciting developments in MS care is the ability to use blood tests to predict who is likely to do well and who may face a harder course. Neurofilament light chain (NfL) is a protein released when nerve fibers are damaged, and it can be measured with a simple blood draw. A study that followed patients for over a decade found that higher baseline NfL levels tracked with faster brain atrophy and were associated with a steeper trajectory of disability worsening over time.¹⁹ Another study found that NfL measured just a few years into the disease could predict who would reach significant disability at the 15-year mark, with those in the highest NfL range about five times more likely to reach that point than those with the lowest levels.²⁰

Perhaps more useful in day-to-day practice is the flip side: low NfL levels were a strong signal of favorable outcomes. One study found that patients below a certain NfL threshold were over four times less likely to develop significant disability.²¹ For patients and clinicians, NfL levels are becoming a way to gauge whether the current treatment is working well enough or whether it is time to consider switching. This kind of objective measurement is relatively new for MS, and it is changing how aggressively clinicians intervene.

The Question of Stopping Treatment Later in Life

As people with MS age and their disease appears stable, many wonder whether they can stop their medications. The answer is not straightforward. A randomized trial (DISCOMS) that enrolled older, stable MS patients found that about 12 percent of those who stopped treatment had new disease activity within two years, compared with roughly 5 percent of those who continued. This failed to meet the study’s threshold for proving that stopping was just as good as continuing.²² A U.S. claims-based study reinforced this concern, finding that stopping treatment was linked to increased emergency visits and relapse-related hospitalizations.²³

A more recent meta-analysis offered a slightly more nuanced picture: when pooling data across studies, the risk of relapse after stopping treatment was not statistically distinguishable from continuing, though the risk of mild adverse events was higher in the discontinuation group.²⁴ The tension between these findings reflects the difficulty of the question: some genuinely stable patients may tolerate stopping, but right now there is no reliable way to identify who they are. Most neurologists default to continuing treatment, especially given the evidence that subclinical damage can accumulate without obvious symptoms.

Stem Cell Transplantation as a Treatment Option

For some people, particularly those with aggressive relapsing MS who have not responded well to standard therapies, autologous hematopoietic stem cell transplantation (aHSCT) has emerged as a potent option. The procedure essentially resets the immune system. Long-term data from a large international registry found that among people with relapsing MS, about 71 percent remained free of disability worsening at 10 years after transplant. For those with progressive MS, the figure was about 57 percent at 10 years, which is still a meaningful result given that these patients had often failed other treatments.²⁵ Younger age and having a relapsing form of the disease predicted better outcomes after transplant.²⁶

The procedure carries real risk. Earlier transplant cohorts had treatment-related mortality around 3 percent, though safety has improved markedly: one long-term study reported no transplant-related deaths after 2007.²⁵ There is also evidence that quality of life and fatigue scores can remain improved for up to a decade following transplant.²⁷ aHSCT is not appropriate for everyone, but for the right candidate, it can offer a degree of disease control that conventional drugs do not match.

Disparities in Who Benefits

The improving life expectancy figures do not apply equally across all populations. Social determinants of health, including race, income, education level, and access to specialty care, significantly shape MS outcomes. A review in JAMA Neurology noted that Black individuals in the U.S. face both higher MS-related mortality and greater health disparities driven by lower income, lower health literacy, and unequal access to neurologists.²⁸ A narrative review in Nature Reviews Neurology reinforced these findings, identifying racial background, employment status, and social support as factors with demonstrated effects on MS outcomes.²⁹

These disparities matter practically. The life expectancy gains of the past two decades have been driven by timely access to potent therapies, multidisciplinary care teams, and proactive infection prevention. A systematic review found improved outcomes across multiple domains when MS patients had access to coordinated care involving neurologists, nurses, physiotherapists, psychologists, and other specialists.³⁰ People who lack insurance, who live far from an MS center, or who face barriers to regular follow-up may not see the same improvements that clinical trials and registry studies report. When someone asks how long they can live with MS, the answer depends not just on their biology but on their circumstances.